1. Home
  2. CYTK vs HHH Comparison

CYTK vs HHH Comparison

Compare CYTK & HHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • HHH
  • Stock Information
  • Founded
  • CYTK 1997
  • HHH 2010
  • Country
  • CYTK United States
  • HHH United States
  • Employees
  • CYTK N/A
  • HHH N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • HHH Real Estate Investment Trusts
  • Sector
  • CYTK Health Care
  • HHH Real Estate
  • Exchange
  • CYTK Nasdaq
  • HHH Nasdaq
  • Market Cap
  • CYTK 4.6B
  • HHH 4.6B
  • IPO Year
  • CYTK 2004
  • HHH N/A
  • Fundamental
  • Price
  • CYTK $49.76
  • HHH $81.91
  • Analyst Decision
  • CYTK Buy
  • HHH Buy
  • Analyst Count
  • CYTK 15
  • HHH 2
  • Target Price
  • CYTK $75.57
  • HHH $85.00
  • AVG Volume (30 Days)
  • CYTK 2.7M
  • HHH 334.3K
  • Earning Date
  • CYTK 11-05-2025
  • HHH 11-03-2025
  • Dividend Yield
  • CYTK N/A
  • HHH N/A
  • EPS Growth
  • CYTK N/A
  • HHH N/A
  • EPS
  • CYTK N/A
  • HHH 4.43
  • Revenue
  • CYTK $85,738,000.00
  • HHH $1,770,945,000.00
  • Revenue This Year
  • CYTK $330.96
  • HHH N/A
  • Revenue Next Year
  • CYTK $73.41
  • HHH $21.07
  • P/E Ratio
  • CYTK N/A
  • HHH $18.49
  • Revenue Growth
  • CYTK 2635.74
  • HHH 80.45
  • 52 Week Low
  • CYTK $29.31
  • HHH $61.41
  • 52 Week High
  • CYTK $59.39
  • HHH $87.77
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 63.01
  • HHH 53.41
  • Support Level
  • CYTK $49.22
  • HHH N/A
  • Resistance Level
  • CYTK $53.58
  • HHH $82.32
  • Average True Range (ATR)
  • CYTK 2.54
  • HHH 1.25
  • MACD
  • CYTK 0.29
  • HHH -2.60
  • Stochastic Oscillator
  • CYTK 76.53
  • HHH 99.49

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About HHH Howard Hughes Holdings Inc.

Howard Hughes Holdings Inc owns, manages, and develops commercial, residential, and mixed-use real estate throughout the USA. Its portfolio is strategically positioned to meet and accelerate development based on market demand, resulting in one of the strongest real estate platforms in the country. It operates through four business segments: Operating Assets, MPCs, Strategic Developments and Seaport.

Share on Social Networks: